Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Session IV: Modulators of Immune Escape Mechanisms

Myeloid-derived suppressor cells in cancer

Vincenzo Bronte
Vincenzo Bronte
Istituto Oncologico Veneto and Venetian Institute for Molecular Medicine, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Active suppression of tumor-specific T lymphocytes can limit both immune surveillance and immunotherapy. Several mouse tumors, either transplantable or spontaneously arising, alter the normal myelopoiesis and cause the expansion of a population of CD11b+/Gr-1+ cells in the blood, lymphoid organs and at the tumor site. These cells were recently defined as myeloid-derived suppressor cells (MDSCs). MDSCs are likely part of a conserved response to inflammatory signals and are harnessed by growing tumors to exert different functions, including support for stroma and neovasculature formation. However, in addition to their direct activity on tumor growth, MDSCs are now recognized as potent negative regulators of tumor-specific CD8+ T cells.

While tumor-recruited CD11b+ myeloid cells were known mediators of tumor-associated immune dysfunctions, the true nature of these suppressive cells and the fine biochemical pathways governing their immunosuppressive activity have been clarified only in last years. By means of combined genome-wide expression profiling, biochemical analyses, and functional studies in knock out mice, we identified a population of CD11b+, inflammatory-type monocytes expressing the alpha chain of the IL-4 receptor (IL-4Rα - CD124), that is elicited by growing tumors and activated by IFN-γ released from T lymphocytes. CD11b+/CD124+ cells produce IL-13 and IFN-γ and integrate the downstream signals of these cytokines to trigger the molecular pathways suppressing antigen-activated CD8+ T lymphocytes. In particular, IL-13 and IFN-γ cooperate in CD11b+/CD124+ cells to activate the enzymes arginase and nitric oxide synthase that metabolize the amino acid L-arginine and are among the final mediators of the suppressive machinery acting on CD8+ T lymphocytes. These suppressor cells challenge the current dogma of classic and alternative macrophage activation and show how the inflammatory response elicited by tumors has detrimental effects on the adaptive immune system. Moreover, definition of the metabolic pathways used by MDSCs to alter T lymphocyte reactivity to the antigens has unveiled potential targets for novel therapeutic interventions. At least two families of unrelated drugs, nitroaspirin and phosphodiesterase 5 inhibitors, were shown to affect the immunosuppressive pathways of MDSCs in preclinical tumor models.

In addition to their prevalent activity on CD8+ T cells, recent data support a role for MDSCs in the activation of T regulatory lymphocytes (Tregs). In particular, MDSCs can uptake tumor-associated antigens, present them to naturally-occurring, tumor-specific Tregs inducing them to proliferate. Moreover, therapeutic interventions, which effectively abrogate the immunosuppressive machinery of MDSCs, also results in the reduction of Treg numbers in tumor-bearing hosts. In cancer patients, the nature of MDSCs is still poorly defined since evidence exists for both monocytic and granulocytic features. We recently found that myeloid cells with immunosuppressive properties accumulate both in mononuclear and polymorphonuclear fractions of circulating blood leukocytes of patients with colon cancer and melanoma, thus confirming the generalized alteration in the homeostasis of the myeloid compartment observed in mouse models. Similarly to mouse MDSCs, CD124 is up-regulated in both myeloid populations but its presence correlates with an immunosuppressive phenotype only when mononuclear cells, but not granulocytes, of tumor-bearing patients are considered.

In order to dissect the molecular pathways involved in MDSC differentiation, we recently defined in vitro culture conditions to elicit MDSCs from human and mouse bone marrow cells. These cells share phenotype and functions of tumor-induced MDSCs and can be adoptively transferred to recipient mice inducing antigen tolerance. Interestingly, adoptive transfer of syngeneic bone marrow-derived MDSCs to diabetic mice transplanted with allogeneic pancreatic islets resulted in the allograft acceptance of the and long term correction of the diabetic status.

Preclinical evidence strongly supports a beneficial effect of approaches targeting either MDSCs or their inhibitory pathways on the anti-tumor immune response, either endogenous or elicited by immunization/adoptive transfer of tumor-specific T cells. Development of new treatments will thus have a double role: defining new immune modulators to improve the effectiveness of the immunotherapy of cancer but also clarify better the role of MDSCs in tumors of different derivation as well as in various stages of cancer progression. On the other side of the same coin, techniques allowing generation and adoptive transfer of MDSCs might represent a novel tool to control diseases characterized by excessive activation of the immune systems such as either autoimmune diseases or allograft rejection.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Vincenzo Bronte
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 2)
January 2008
Volume 8, Issue Suppl 2
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Myeloid-derived suppressor cells in cancer
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Myeloid-derived suppressor cells in cancer
Vincenzo Bronte
Cancer Immun January 1 2008 (8) (Suppl 2) 16;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Myeloid-derived suppressor cells in cancer
Vincenzo Bronte
Cancer Immun January 1 2008 (8) (Suppl 2) 16;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Checkpoint blockade in tumor therapy: New insights and opportunities
  • PD-1, PD-L1 and their ligands: Regulating the balance between T cell activation and tolerance
Show more Session IV: Modulators of Immune Escape Mechanisms
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement